(87) - Donor Specific Antibodies Associated with Micro- and Macrovascular Coronary Disease and Restrictive Myocardial Damage in Heart Transplanted Patients

Abstract

s S41 II. Of the Class II antibodies, 53%, 42.6%, and 4.4% were DR, DQ, and DP respectively. The Class I was predominately against B (54.3%) followed by Cw (28.6%) and A (17.1%). The 1, 2 and 3 year survival after the development of Class I DSA was 91%, 81% and 79% and after Class II DSA was 93%, 80%, and 80%, respectively. Conclusion: At five years, more than a third of CTX patients developed DSA, primarily to Class II. Patients who developed DSA were more than twice as likely to have a PRA > = 20. Once a patient developed DSA their mortality in the subsequent 3 years was approximately 20%. Additional studies are warranted to evaluate long-term survival and graft function.